Phase 1 Obesity trials recruiting now

All Obesity trials, every phase

Other phases for Obesity

Phase 1 Obesity trials

• A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
  NCT07465965 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
  NCT07747857 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 12 locations
• A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
  NCT07331389 · Phase: Phase 1 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 1 location
• A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
  NCT06937203 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 16 locations
• A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
  NCT06700538 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 7 locations
• A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
  NCT07767175 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• A Food-Effect Study of CX11 in Healthy Participants
  NCT07349381 · Phase: Phase 1 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 1 location
• A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
  NCT07539415 · Phase: Phase 1 · Ages: 19 Years to 64 Years · Sex: All (male and female) · 1 location
• A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969
  NCT07581431 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
  NCT06842186 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 6 locations
• A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection
  NCT06934408 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants
  NCT06778850 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
  NCT07243171 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
  NCT07566390 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity
  NCT07578584 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
  NCT07557953 · Phase: Phase 1 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight
  NCT07525791 · Phase: Phase 1 · Ages: 18 Years to 64 Years · Sex: Female · 1 location
• A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant
  NCT07710729 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: Female · 1 location
• A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity
  NCT07508020 · Phase: Phase 1 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight
  NCT07710768 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
  NCT07597018 · Phase: Phase 1 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo
  NCT07757087 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Self-Guided Mobile Intervention for Adults With Binge Eating and Obesity
  NCT06817863 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
  NCT07219589 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants
  NCT06982131 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors
  NCT07463196 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
  NCT07411560 · Phase: Phase 1 · Ages: 18 Years to 64 Years · Sex: Female · 1 location
• A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
  NCT07291232 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
  NCT07239973 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
  NCT07294235 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
  NCT07738614 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
  NCT07665879 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 2 locations
• A Study of HS-20094 in Overweight or Obese Participants
  NCT07057674 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity
  NCT07160400 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
  NCT07654972 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
  NCT06924320 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
  NCT06239116 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 65 Years · Sex: All (male and female) · 7 locations
• A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses
  NCT07280936 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults
  NCT07307274 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants
  NCT07443059 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity
  NCT07768813 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate ALN-2232 in Participants With Obesity
  NCT07463846 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate ALN-6222 in Participants With Obesity
  NCT07624071 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
  NCT06836609 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 4 locations
• A Study to Evaluate MWN109 Injection in Healthy Subjects
  NCT06859853 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate MWN109 Tablets in Healthy Adult Participants
  NCT06938269 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 2 locations
• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
  NCT07675590 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
  NCT07652047 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: Female · 2 locations
• A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
  NCT07102251 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity
  NCT07559136 · Phase: Phase 1 · Ages: 12 Years to 18 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
  NCT07142707 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 4 locations
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults
  NCT07487376 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants
  NCT07230496 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
  NCT07511205 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
  NCT07013643 · Phase: Phase 1 · Ages: 35 Years to 75 Years · Sex: Female · 2 locations
• A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
  NCT07723833 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity
  NCT07725809 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
  NCT07184086 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity
  NCT07693868 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity
  NCT07437079 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight
  NCT07693231 · Phase: Phase 1 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 3 locations
• A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
  NCT07702890 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight
  NCT07628127 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Alpelisib Challenge Test (ACT)
  NCT07778524 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.
  NCT06891287 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Bariatric Surgery Combined With GLP-1 Receptor Agonists Study
  NCT07336862 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Bioequivalence Study of BGM0504 Injection
  NCT07382908 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Bioequivalence Study of GZR18 Injection Before and After CMC Change
  NCT07355738 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: Male · 1 location
• Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants
  NCT07550816 · Phase: Phase 1 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 1 location
• Effect of Insulin Lowering on Lipogenesis
  NCT07403604 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Evaluate LAE102 in Healthy and Overweight/Obese Subjects
  NCT06493084 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
  NCT07166081 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
  NCT07607587 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
  NCT07225816 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Feasibility of Semaglutide in Advanced Lung Disease
  NCT05746039 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• First in Human Study in Subjects With Obesity, But Otherwise Healthy
  NCT06252220 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Graded Insulin Suppression Test P&F
  NCT06592261 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)
  NCT07123779 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Human Models of Selective Insulin Resistance: Alpelisib, Part I
  NCT06354088 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• IBI3042 Study in Healthy Participants and Overweight or Obese Participants
  NCT07793019 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Individualization of Dosage Regimens in Obese Patients: Application to Acyclovir
  NCT05589688 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• Integrated Traditional Chinese Medicine Day Care Program for Metabolic Syndrome
  NCT06703788 · Phase: Phase 1, Phase 2 · Ages: 20 Years to 75 Years · Sex: All (male and female) · 1 location
• Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism
  NCT04328337 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 2 locations
• Liver Adiposity Effects on Pediatric Statin
  NCT04903223 · Phase: Phase 1 · Ages: 8 Years to 21 Years · Sex: All (male and female) · 1 location
• Metabolic Effects of Angiotensin-(1-7)
  NCT02646475 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Mitigating the Pro-inflammatory Phenotype of Obesity
  NCT04934228 · Phase: Phase 1 · Ages: 18 Years to 79 Years · Sex: All (male and female) · 1 location
• ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
  NCT05542407 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 1 location
• Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
  NCT07095517 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• Pharmacogenetics of Response to GLP1R Agonists
  NCT05071898 · Phase: Phase 1 · Ages: 18 Years to 89 Years · Sex: All (male and female) · 1 location
• Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study
  NCT06345560 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 45 Years · Sex: Female · 1 location
• Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
  NCT07803809 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 2 locations
• Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
  NCT07245771 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
  NCT07785934 · Phase: Phase 1 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 1 location
• Phase I Study of XTL6001 Injection in Healthy and Obese Subjects
  NCT07205432 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents
  NCT07693426 · Phase: Phase 1 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 5 locations
• Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
  NCT06575738 · Phase: Phase 1 · Ages: 12 Years to 24 Years · Sex: All (male and female) · 1 location
• Pilot Testing a Novel Approach to Pediatric Obesity Treatment
  NCT06755827 · Phase: Phase 1, Phase 2 · Ages: 11 Years to 14 Years · Sex: All (male and female) · 1 location
• Prevention of Progression of Prediabetes, Obesity and CV Risk
  NCT06446531 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Probiotics and Gut Health
  NCT03418857 · Phase: Phase 1, Phase 2 · Ages: 55 Years to 75 Years · Sex: All (male and female) · 1 location
• Project SHINE (Sleep Health INitiative for Equity): Culturally Informing a Sleep Extension Intervention for African American Adults
  NCT06226077 · Phase: Phase 1, Phase 2 · Ages: 21 Years to 75 Years · Sex: All (male and female) · 1 location

Showing 100 of 124 recruiting trials.

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.